Inhibitors of serine proteases, particularly HCV NS3-NS4A...

Details Inhibitors of serine proteases, particularly HCV NS3-NS4A... Inhibitors of serine proteases, particularly HCV NS3-NS4A...

2007-03-09

2011-10-18

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S405000, C514S255060

Reexamination Certificate

active

08039623

ABSTRACT:
The present invention relates to compounds of formula I:or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

REFERENCES:
patent: 5484801 (1996-01-01), Al-Razzak et al.
patent: 5807876 (1998-09-01), Armistead et al.
patent: 5948436 (1999-09-01), Al-Razzak et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6054472 (2000-04-01), Armistead et al.
patent: 6265380 (2001-07-01), Tung et al.
patent: 6344465 (2002-02-01), Armistead et al.
patent: 6498178 (2002-12-01), Stamos et al.
patent: 6541496 (2003-04-01), Armistead et al.
patent: 6608067 (2003-08-01), Tung et al.
patent: 6617309 (2003-09-01), Tung et al.
patent: 6909000 (2005-06-01), Farmer et al.
patent: 7109172 (2006-09-01), Britt et al.
patent: 7208600 (2007-04-01), Cottrell et al.
patent: 7241796 (2007-07-01), Farmer et al.
patent: 7273885 (2007-09-01), Pitlik et al.
patent: 2003/0236242 (2003-12-01), Perni et al.
patent: 2004/0077600 (2004-04-01), Tung et al.
patent: 2004/0266731 (2004-12-01), Tung et al.
patent: 2005/0080017 (2005-04-01), Cottrell et al.
patent: 2005/0090450 (2005-04-01), Farmer et al.
patent: 2005/0119189 (2005-06-01), Cottrell et al.
patent: 2005/0137139 (2005-06-01), Perni et al.
patent: 2005/0197299 (2005-09-01), Babine et al.
patent: 2005/0215486 (2005-09-01), Cottrell et al.
patent: 2006/0211629 (2006-09-01), Britt et al.
patent: 2007/0179167 (2007-08-01), Cottrell et al.
patent: 2007/0292933 (2007-12-01), Pitlik et al.
patent: 2008/0045480 (2008-02-01), Farmer et al.
patent: 0675112 (1995-10-01), None
patent: 94/14436 (1994-07-01), None
patent: 95/07696 (1995-03-01), None
patent: 95/09614 (1995-04-01), None
patent: 97/40028 (1997-10-01), None
patent: 98/17679 (1998-04-01), None
patent: 98/40381 (1998-09-01), None
patent: 0009543 (2000-02-01), None
patent: 00/56331 (2000-09-01), None
patent: 01/74768 (2001-10-01), None
patent: 02/08244 (2002-01-01), None
patent: 02/18369 (2002-03-01), None
patent: 02/060926 (2002-08-01), None
patent: 03/006490 (2003-01-01), None
patent: 03/035060 (2003-05-01), None
patent: 03/064416 (2003-08-01), None
patent: 2004/037855 (2004-05-01), None
patent: 2004/092161 (2004-10-01), None
patent: 2004/096162 (2004-10-01), None
patent: 2004/103996 (2004-12-01), None
Alberti, A. et al., “Natural History of Hepatitis C,” J. Hepatology, 31., (Suppl. 1) pp. 17-24 (1999).
Alter, M. J. “Hepatitis C Virus Infection in the United States,” J. Hepatology, 31., (Supp. 1), pp. 88-91 (1999).
Alter, M.J. et al., The Epidemiology of Viral Hepatitis in the United States, Gastroenterol. Clin. North Am., 23, pp. 437-455 (1994).
Bartenschlager, R. et al., “Nonstructual Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions,” J. Virol., 67, pp. 3835-3844 (1993).
Chambers, T.J. et al., “Evidence that the N-terminal Domain of Nonstructual Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein,” Proc. Natl. Acad. Sci. USA, 87, pp. 8898-8902 (1990).
Choo, Q.L. et al., “Genetic Organization and Diversity of the Hepatitis C Virus.” Proc. Natl. Acad. Sci. USA, 88 pp. 2451-2455 (1991).
Clayette, P. et al. “IFN-tau, A New Interferon Type I with Antiretroviral activity” Pathol. Biol. (Paris) 47, pp. 553-559 (1999).
Davis et al., “Future Options for the Management of Hepatitis C.” Seminars in Liver Disease 19, pp. 103-112 (1999).
Field, L. et al., “Organic Disulfides and Related Substances. 42. Synthesis and Properties of Some Tertiary Disulfides, Especially Involving Penicillamine,” J. Org. Chem., pp. 2624-2629 (1979).
Grakoui, E. et al., “Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites,” J. Virol., 67, pp. 2832-2843 (1993).
Grakoui, A. et al., “Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products,” J. Virol., 67, pp. 1385-1395 (1993).
Holladay, M.W. et al., “Dual Antagonists of Platelet Activating Factor and Histamine. Identification of the Structual Requirements for Dual Activity of N-Acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta-[1,2-b]pyridin-11-ylidene) piperdines,” J. Med. Chem., 34, pp. 457-461 (1991).
Iwarson, S. “The Natural Course of Chronic Hepatitis C,” FEMS Microbiology Reviews, 14, pp. 201-204 (1994).
Janssen, H. L. A. et al., “Suicide Associated with Alfa-Interferon Therapy for Chronic Viral Hepatitis,” J. Hepatol., 21, pp. 241-243 (1994).
Johansson, Anja et al., “Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase): A comparative study of different c-terminals,” Bioorganic & Medicinal Chemistry, Elsevier Science Ltd. GB, vol. 11, pp. 2551-2568 (2003).
Kanamasa, S. et al., “Highly Diastereoselective Michael Addition of Lithiated Camphor Imines of Glycine Esters to a, B-Unsaturated Esters. Synthesis of Optically Pure 5-Oxo-2,4-pyrrolidinedicaboxylates of Unnatural Setroechemistry,” J. Org. Chem, 56, pp. 2875-2883 (1991).
Kao, J.H. et al., “Efficicacy of Consensus Interferon in the Treatment of Chronic Hepatitis C” J. Gastroenterol. Hepatol. 15, pp. 1418-1423 (2000).
Kato, N. et al., “Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis,” Proc. Natl. Acad. Sci. USA, 87 pp. 9524-9528 (1990).
Kempf, D.J. et al., “Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1, 6-diphenylhexane-3,4-diol,” J. Med. Chem., pp. 320-330 (1993).
Kew, M.C. “Hepatitis C and Hepatocellular Carcinoma”, FEMS Microbiology Reviews, 14, pp. 211-220 (1994).
Lavanchy, D. “Global Surveillance and Control of Hepatitis C,” J. Viral Hepatitis, 6, pp. 35-47 (1999).
Lin, C. et al., “Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage Requirements and Processing Kinetics”, J. Virol., 68 pp. 8147-8157 (1994).
Markland, W. et al., “Board-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparision with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon,” Antimicrobial & Antiviral Chemotherapy, 44, p. 859 (2000).
Moradpour, D. et al., “Current and Evolving Therapies for Hepatitis C,” Eur. J. Gastroenterol. Hepatol., 11, pp. 1199-1202 (1999).
Perni, Robert B. et al., “Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 Proline Variants,” Bioorganic & Medicinal Chemistry Letters, Oxfrod GB, vol. 14, pp. 1939-1942 (2004).
Perni, Robert B. et al., “Inhibitors of hepatitis C virus NS3.4A protease 2. Warhad SAR and optimization,” Bioorganic & Medicinal Chemistry Letters, vol. 14, pp. 1441-1446 (2004).
Perni, Robert B. et al.,Inhibitors of hepatitis C virus NS3cntdot4A protease 1. Non-charged tetrapeptide variants, Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 4059-4063 (2003).
Poliakov, A. et al., “Structure-activity relationship for the selectivity of hepatitis C virus NS3 protease inhibitors” BBA-General Subject, Elsevier Science Publishers, NL, vol. 1672, 51-59 (2004).
Reddy, K.R. et al.

Affiliated with

Also associated with

Rating

Inhibitors of serine proteases, particularly HCV NS3-NS4A... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of serine proteases, particularly HCV NS3-NS4A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of serine proteases, particularly HCV NS3-NS4A... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4292032